Back to search

Article

Preserved T-cell Response in anti-CD20 Treated Multiple Sclerosis Patients Following SARS-CoV-2 Vaccination

2021-12-09

Abstract excerpt

<title>Abstract</title> <p>The SARS-CoV-2 pandemic has tremendous implications for the management of patients with autoimmune conditions such as multiple sclerosis (MS) under immune therapies targeting CD20<sup>+</sup> B cells (aCD20). We here investigated humoral and cellular immune responses, including neutralization against SARS-CoV-2 WT and delta variant and T cell responses of aCD20-treated MS patients follo...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
57a24cee-8327-500f-940c-5d5a7310e85e
DOI
10.21203/rs.3.rs-1109886/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Preserved T-cell Response in anti-CD20 Treated Multiple Sclerosis Patients Following SARS-CoV-2 VaccinationDOI 10.21203/rs.3.rs-1109886/v1
Humoral immune responses remain quantitatively impaired but improve qualitatively in anti-CD20 treated patients with multiple sclerosis after three or four COVID-19 vaccinationsSemantic proximity
Altered cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapySemantic proximity
B- and T-cell Specific Responses to Vaccination against SARS-CoV-2 in Anti-CD20 Treated Patients with Relapsing-Remitting or Progressive Form of Multiple Sclerosis Reveal Immunosenescent FeaturesSemantic proximity
Effect of different disease-modifying therapies on humoral response to BNT162b2 vaccine in Sardinian multiple sclerosis patientsSemantic proximity
T cell responses to SARS-CoV-2 vaccination in people with multiple sclerosis differ between disease-modifying therapiesSemantic proximity
Patients treated with anti-CD20 therapy can mount robust T cell responses to mRNA-based COVID-19 vaccinesSemantic proximity
Longitudinal follow-up of SARS-CoV-2 vaccine- induced antibody responses in patients with multiple sclerosis treated with anti-CD20 therapySemantic proximity
Durable T cell immunity to COVID-19 vaccines in MS patients on B cell depletion therapySemantic proximity
Distinct Patterns of Humoral and Cellular Immune Responses Following SARS-CoV-2 mRNA Vaccination in Patients With Immune-Mediated Neurological Disorders on Anti-CD20 Therapy: A Prospective Cohort StudySemantic proximity
Long-standing COVID-19 disease in immunedeficient patients; case reports and literature reviewSemantic proximity
Immune dynamics in SARS-CoV-2 experienced immunosuppressed rheumatoid arthritis or multiple sclerosis patients vaccinated with mRNA-1273Semantic proximity
Immune profiling of COVID-19 vaccine responses in people with multiple sclerosis on B cell-depleting therapySemantic proximity
Select a neighboring publication to make it the new centre.